Table IV.

Outcomes of Matched-Cohort Analysis: Post-CY versus Tacrolimus/MTX

		Hazard Ratio (95% CI)	p-value
Median Follow-up (range)
Post-Cy	37 months (24–43)
Tacrolimus/MTX	20 months (12–63)
Acute GVHD II–IV
Post-CY	46% (32–65)	2.8 (1.1–6.8)
Tacrolimus/MTX	19% (10–37)	Ref.	0.02
Acute GVHD III–IV
Post-CY	14% (6–32)
Tacrolimus/MTX	0% (2–70)	N/E	0.02
Chronic GVHD at 1 year
Post-CY	20% (10–39)	1.0 (0.4–2.8)
Tacrolimus/MTX	22% (12–40)	Ref.	0.9
Day-100 TRM
Post-CY	11% (4–27)	2.1 (0.4–11.6)
Tacrolimus/MTX	5% (1–21)	Ref.	0.4
2-Year TRM
Post-CY	35% (23–54)	3.3 (1.1–8.5)
Tacrolimus/MTX	13% (6–30)	Ref.	0.035
Day-100 CMV-Reactivation
Post-CY		1.3 (0.6–2.6)
Tacrolimus/MTX		Ref.	0.5
Progression at 2-years
Post-CY	35% (23–54)	0.9 (0.4–1.9)
Tacrolimus/MTX	44% (30–63)	Ref.	0.8
PFS at 2 years
Post-CY	22% (10–36)	1.6 (0.9–2.8)
Tacrolimus/MTX	43% (27–58)	Ref.	0.1
OS at 2 years
Post-CY	30% (16–45)	1.9 (1.02–3.2)
Tacrolimus/MTX	52% (35–67)	Ref.	0.04